Who are rtPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tenecteplase or Alteplase, Trasylol, Cyklokapron, Amicar, Reteplase 10 U, Tranexamic Acid (Topical).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rtpa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

rtPA — Competitive Intelligence Brief

rtPA (rtPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent; tissue plasminogen activator (tPA). Area: Cardiovascular; Neurology.

marketed Fibrinolytic agent; tissue plasminogen activator (tPA) Plasminogen; fibrin Cardiovascular; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

rtPA (rtPA) — Hui-Sheng Chen. rtPA is a tissue plasminogen activator that converts plasminogen to plasmin, directly dissolving fibrin clots through fibrinolysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rtPA TARGET	rtPA	Hui-Sheng Chen	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Plasminogen; fibrin
Tenecteplase or Alteplase	Tenecteplase or Alteplase	Insel Gruppe AG, University Hospital Bern	marketed	Tissue plasminogen activator (tPA); fibrinolytic agent	Plasminogen; fibrin
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Reteplase 10 U	Reteplase 10 U	The University of Texas Health Science Center, Houston	marketed	Fibrinolytic agent; tissue plasminogen activator (tPA)	Fibrin; plasminogen
Tranexamic Acid (Topical)	Tranexamic Acid (Topical)	Total Definer Research Group	marketed	Antifibrinolytic agent	Plasminogen / Plasmin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent; tissue plasminogen activator (tPA) class)

Cedars-Sinai Medical Center · 1 drug in this class
Hui-Sheng Chen · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rtPA — Competitive Intelligence Brief. https://druglandscape.com/ci/rtpa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab